CN108426867B - 在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法和应用 - Google Patents
在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法和应用 Download PDFInfo
- Publication number
- CN108426867B CN108426867B CN201810642154.9A CN201810642154A CN108426867B CN 108426867 B CN108426867 B CN 108426867B CN 201810642154 A CN201810642154 A CN 201810642154A CN 108426867 B CN108426867 B CN 108426867B
- Authority
- CN
- China
- Prior art keywords
- mof
- solution
- probe
- mol
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 26
- 229960000479 ceftriaxone sodium Drugs 0.000 title claims abstract description 25
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 title claims abstract description 25
- 239000000523 sample Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000013078 crystal Substances 0.000 claims abstract description 6
- 239000003446 ligand Substances 0.000 claims abstract description 6
- MMEDJBFVJUFIDD-UHFFFAOYSA-N 2-[2-(carboxymethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC=C1CC(O)=O MMEDJBFVJUFIDD-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000005303 weighing Methods 0.000 claims abstract description 5
- KJDRSWPQXHESDQ-UHFFFAOYSA-N 1,4-dichlorobutane Chemical compound ClCCCCCl KJDRSWPQXHESDQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005457 ice water Substances 0.000 claims abstract description 4
- -1 polytetrafluoroethylene Polymers 0.000 claims abstract description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims abstract description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 238000000967 suction filtration Methods 0.000 claims abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 abstract description 13
- 229940088710 antibiotic agent Drugs 0.000 abstract description 13
- 229910021645 metal ion Inorganic materials 0.000 abstract description 12
- 239000012491 analyte Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 27
- 229960004099 azithromycin Drugs 0.000 description 9
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 9
- 238000010791 quenching Methods 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 6
- 229960003022 amoxicillin Drugs 0.000 description 6
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 6
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 6
- 229960003644 aztreonam Drugs 0.000 description 6
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 6
- 229960005361 cefaclor Drugs 0.000 description 6
- 229960002129 cefixime Drugs 0.000 description 6
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 6
- 229960002588 cefradine Drugs 0.000 description 6
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 6
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 4
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 3
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 3
- JYXACOFERDBGGQ-RHSMWYFYSA-N cefathiamidine Chemical compound S1CC(COC(C)=O)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CSC(NC(C)C)=NC(C)C)[C@H]21 JYXACOFERDBGGQ-RHSMWYFYSA-N 0.000 description 3
- 229950005040 cefathiamidine Drugs 0.000 description 3
- 229960003016 cefoxitin sodium Drugs 0.000 description 3
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 3
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 3
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 description 3
- 229940099584 lactobionate Drugs 0.000 description 3
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 3
- 229960001595 lincomycin hydrochloride Drugs 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229960005404 sulfamethoxazole Drugs 0.000 description 3
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000012984 antibiotic solution Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010297 mechanical methods and process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- VWSRHOIRMGHAPR-UHFFFAOYSA-N 2-methyl-1-[4-(2-methylimidazol-1-yl)butyl]imidazole Chemical compound CC1=NC=CN1CCCCN1C(C)=NC=C1 VWSRHOIRMGHAPR-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 239000013180 Zr(iv)-based metal–organic framework Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000005355 lead glass Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000012621 metal-organic framework Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013384 organic framework Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Cephalosporin Compounds (AREA)
Abstract
本发明公开了一种在水中检测Fe3+和抗生素头孢曲松钠的MOF‑Cd探针及其制备方法和应用,包括以下步骤:配体bbi的制备:取咪唑0.05~0.1moL和氢氧化钠0.05~0.1moL溶于DMSO中于60℃下反应2h后,称取1,4‑二氯丁烷0.025~0.5moL分多次加入上述溶液,持续反应2~3h后,将溶液倒入含有500mL冰水混合的烧杯中,静置一夜,得到大量白色针状产物,抽滤得到白色产物,晾干后备用;取20~40mg bbi,邻苯二乙酸20~40mg,0.0494~0.1g Cd(NO3)2于DMA中,搅拌溶解置于聚四氟乙烯内衬中,在80℃下反应40~48h后,得到无色透明单晶,即为MOF‑Cd探针。可以在水中对分析物进行检测。在不同pH条件下和在其他金属离子和抗生素的干扰下,仍然不影响检测的效果。
Description
技术领域
本发明属于分析化学领域,具体设计了一种使用bbi=1,4-双(2-甲基咪唑-1-基)丁烷和邻苯二乙酸作为配体,并使用Cd(NO3)2·4H2O作为金属节点来构建新的具有稳定荧光性质的MOF-Cd材料,可用于高选择性、高灵敏度、高稳定性检测水中的Fe3+和抗生素头孢曲松钠。
背景技术
随着公众健康和水质日益受到关注,废水对污染检测的需求也越来越大。金属离子污染会对人类和其他生物造成损害和疾病,已成为一个严重的环境问题。作为一种重要的有机污染物,抗生素被广泛用于治疗人类和动物的细菌感染。过量使用抗生素会导致地下水和地表水中高浓度的抗生素残留物,饮用水中检测到各种抗生素。因此,开发一种检测水中金属离子和抗生素污染物的方法是非常必要的。
到目前为止,常用的检测方法主要为机械方法,如液相色谱与紫外检测,毛细管电泳,离子淌度光谱,质谱,拉曼光谱。然而,这些机械方法不仅需要培训人员和复杂的设备,但也耗时,昂贵。近年来,科学工作者开始研究使用MOFs作为荧光探针检测 Fe3+和头孢曲松钠。Bin Wang等人合成高度稳定的基于Zr(IV)的金属有机框架用于检测水中的抗生素,其中对抗生素的检测限为90ppb(Bin Wang,Xiu-Liang Lv,Dawei Feng, Lin-Hua Xie,JianZhang,Ming Li,Yabo Xie,Jian-Rong Li,and Hong-Cai Zhou,Highly Stable Zr(IV)-Based Metal-Organic Frameworks for the Detection and Removal of Antibioticsand Organic Explosives in Water。虽然检测限较低,但是通常在实际生活环境系统中,金属离子和抗生素会在不同条件下存在,因此我们需要在不同条件下寻求更稳定的探针材料是很重要的。
发明内容
本发明的目的是针对现有技术的不足提供一种在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法,降低检测限,并且可以在不同pH和不同金属离子存在下对Fe3+和头孢曲松钠进行检测。
一种在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针的制备方法,包括以下步骤:配体bbi的制备:取咪唑0.05~0.1moL和氢氧化钠0.05~0.1moL溶于DMSO中于 60℃下反应2h后,称取1,4-二氯丁烷0.025~0.5moL分多次加入上述溶液,持续反应2 ~3h后,将溶液倒入含有500mL冰水混合的烧杯中,静置一夜,得到大量白色针状产物,抽滤得到白色产物,晾干后备用;取20~40mg bbi,邻苯二乙酸20~40mg,0.0494~0.1 g Cd(NO3)2于DMA中,搅拌溶解置于聚四氟乙烯内衬中,在80℃下反应40~48h后,得到无色透明单晶,即为MOF-Cd探针。
所述的制备方法制备的在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针。
所述的MOF-Cd探针在检测Fe3+和头孢曲松钠中的应用。
本发明具有以下优点:首先,可以在水中对分析物进行检测。其次,相比较其他文献报道的方法检测限更低。最后,在不同pH条件下和在其他金属离子和抗生素的干扰下,仍然不影响检测的效果。
附图说明
图1:所制备得到的MOF-Cd结构;(a)MOF-Cd不对称单元;(b)Cd(II)的配位结构;(c)MOF-Cd的二维结构;(d)MOF-Cd的三维结构
图2:室温下MOF-Cd溶液的UV-vis吸光度和荧光光谱。
图3:向MOF-Cd溶液中加入不同金属离子后的荧光猝灭图。
图4:每次添加5μL Fe3+和Fe3+的相应校准曲线(Stern-Volmer曲线)。
图6:当其他金属离子和Fe3+同时存在时的荧光图。
图7:向MOF-Cd溶液中加入不同抗生素后的荧光猝灭图。
图8:每次添加1μL头孢曲松钠和头孢曲松钠的相应校准曲线(Stern-Volmer曲线)。
图10:当其他抗生素和头孢曲松钠同时存在时的荧光图。
具体实施方式
以下结合具体实施例,对本发明进行详细说明。
下面结合附图及具体实例对本发明做进一步的说明。本发明以Fe3+,Eu3+,La3+, Y3 +,Ba2+,Ni2+,Co2+,Ag+,Zn2+,Sr2+,Cd2+,K+,Mn2+,Na+,Li+,Mg2+,Ca2+为金属离子,以SXT(磺胺甲恶唑),MTR(甲硝唑片),CFM(头孢克圬),CED(头孢拉定),CEC(头孢克洛),CSU(头孢硫脒),FOX(头孢西丁钠),ATM(氨曲南),GEN(硫酸庆大霉素),AZM(阿奇霉素),AMX(阿莫西林),ERY(琥乙红霉素), AMK(阿卡米星),CRO(头孢曲松钠),PEN(青霉素钠),AZL(乳糖酸阿奇霉素), LIN(盐酸林可霉素)为抗生素,将所合成的MOF-Cd溶液对Fe3+和头孢曲松钠进行选择性检测。
实施例1制备MOF-Cd溶液的具体实施例:
首先合成配体bbi:称取咪唑(0.05~0.1moL)和氢氧化钠(0.05~0.1moL)溶于DMSO (10mL)中于60℃下反应2h后,称取1,4-二氯丁烷(0.025~0.5moL)分多次加入上述溶液,持续反应2~3h后,将溶液倒入含有500mL冰水混合的烧杯中,静置一夜,得到大量白色针状产物,抽滤得到白色产物,晾干后备用。
然后称取bbi(20~40mg),邻苯二乙酸(20~40mg),Cd(NO3)2(0.0494~0.1g)于DMA(10mL)中,搅拌溶解置于聚四氟乙烯内衬中,在80℃下反应40~48h后,得到无色透明单晶。图1为所得到的MOF-Cd结构。
将20mg单晶加入到5mLDMSO的离心管中超声分散,然后配置10-2moL/L的金属离子溶液和抗生素溶液。用移液枪取150μL的MOF-Cd溶液于离心管中定容至5mL,然后加入一定量的检测溶液。图2为MOF-Cd溶液的UV-vis吸光度和荧光光谱。
MOF-Cd作为荧光探针对Fe3+和头孢曲松钠的检测试验:
实施例2:MOF-Cd作为荧光探针对Fe3+的检测
向MOF-Cd溶液中加入150μL的金属离子溶液,分别加入Fe3+,Eu3+,La3+,Y3+, Ba2+,Ni2+,Co2+,Ag+,Zn2+,Sr2+,Cd2+,K+,Mn2+,Na+,Li+,Mg2+,Ca2+。图3 中Fe3+对MOF-Cd溶液的荧光有明显的下降。
在MOF-Cd溶液中,当Fe 3+的量从0μL增加到40μL时,MOF-Cd的荧光强度单调且急剧下降,图4中随着Fe3+浓度的增加,MOF-Cd溶液的荧光强度逐渐猝灭。这表明MOF-Cd作为荧光探针可以对Fe3+高度敏感。通过Stern-Volmer(SV)方程可以定量解释荧光淬灭效率,还可以计算检测限:其中I0是分析物之前的荧光强度,I是分析物之后的荧光强度,Ksv是猝灭常数(M-1),[Q]是分析物的摩尔浓度。当Fe3+浓度增加到 0.065mmoL/L时,几乎完全猝灭。根据图4中的数据,Ksv是9×106M-1。基于空白溶液荧光强度的三次重复测量的标准偏差(σ),检测限(3σ/Ksv)计算为69ppb。
在pH=4~11水溶液中,加入150μLMOF-Cd溶液,再向其中加入40μL Fe3+。图 5中未加Fe3+荧光发生基本不发生变化,加了Fe3+后荧光发生淬灭。
向MOF-Cd溶液中加入150uL金属离子(La3+,Y3+,Ba2+,Ni2+,Co2+,Ag+,Zn2+, Sr2+,Cd2 +,K+,Mn2+,Na+,Li+,Mg2+,Ca2+),再向其中加入40uL Fe3+,这样使得其存在Fe3+的情况下同时也存在其他离子。图6中加入混合离子(M+Fe3+)后所有的离子的荧光强度都淬灭了,说明其他离子没有干扰对Fe3+的检测。
实施例3:MOF-Cd作为荧光探针对头孢曲松钠的检测
向MOF-Cd溶液中加入15μL的抗生素溶液,分别加入SXT(磺胺甲恶唑),MTR (甲硝唑片),CFM(头孢克圬),CED(头孢拉定),CEC(头孢克洛),CSU(头孢硫脒),FOX(头孢西丁钠),ATM(氨曲南),GEN(硫酸庆大霉素),AZM(阿奇霉素), AMX(阿莫西林),ERY(琥乙红霉素),AMK(阿卡米星),CRO(头孢曲松钠),PEN (青霉素钠),AZL(乳糖酸阿奇霉素),LIN(盐酸林可霉素)。图7中头孢曲松钠对 MOF-Cd的荧光有明显的下降。
在MOF-Cd溶液中,当头孢曲松钠的量从0μL增加到7μL时,MOF-Cd的荧光强度单调且急剧下降,图8中随着Fe3+浓度的增加,MOF-Cd溶液的荧光强度逐渐猝灭。通过计算,检测限为55ppb。
在pH=4~11水溶液中,加入150μLMOF-Cd溶液,再向其中加入7μL头孢曲松钠,图9中荧光发生淬灭。
向MOF-Cd溶液中加入15μL抗生素(SXT(磺胺甲恶唑),MTR(甲硝唑片),CFM (头孢克圬),CED(头孢拉定),CEC(头孢克洛),CSU(头孢硫脒),FOX(头孢西丁钠),ATM(氨曲南),GEN(硫酸庆大霉素),AZM(阿奇霉素),AMX(阿莫西林), ERY(琥乙红霉素),AMK(阿卡米星),PEN(青霉素钠),AZL(乳糖酸阿奇霉素), LIN(盐酸林可霉素)),再向其中加入7μL头孢曲松钠,这样使得其存在头孢曲松钠的情况下同时也存在其他抗生素。图10中荧光强度都淬灭了,说明其他抗生素没有干扰对头孢曲松钠的检测。
应当理解的是,对本领域普通技术人员来说,可以根据上述说明加以改进或变换,而所有这些改进和变换都应属于本发明所附权利要求的保护范围。
Claims (2)
1.一种在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针,其特征在于,其制备方法包括以下步骤:配体bbi的制备:取咪唑0.05~0.1 moL和氢氧化钠0.05~0.1 moL溶于DMSO中于60℃下反应2 h后,称取1,4-二氯丁烷0.025~0.5 moL分多次加入上述溶液,持续反应2 ~3h后,将溶液倒入含有500 mL冰水混合的烧杯中,静置一夜,得到大量白色针状产物,抽滤得到白色产物,晾干后备用;取20~40mg bbi,邻苯二乙酸20~40mg,0.0494~0.1 g Cd(NO3)2于DMA中,搅拌溶解置于聚四氟乙烯内衬中,在80℃下反应40~48 h后,得到无色透明单晶,即为MOF-Cd,其名称为:Cd(H2L)(bbi),分子式为:C20H21N4O4Cd。
2.根据权利要求1所述的MOF-Cd探针在检测Fe3+和头孢曲松钠中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810642154.9A CN108426867B (zh) | 2018-06-21 | 2018-06-21 | 在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810642154.9A CN108426867B (zh) | 2018-06-21 | 2018-06-21 | 在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108426867A CN108426867A (zh) | 2018-08-21 |
CN108426867B true CN108426867B (zh) | 2020-06-26 |
Family
ID=63164906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810642154.9A Expired - Fee Related CN108426867B (zh) | 2018-06-21 | 2018-06-21 | 在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108426867B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109467712A (zh) * | 2018-11-06 | 2019-03-15 | 安徽大学 | 一种金属有机骨架MOF-Zn荧光传感器材料及其制备方法和应用 |
CN109884015B (zh) * | 2019-03-07 | 2021-07-06 | 安徽大学 | MOF-Zn荧光传感器在检测氯霉素中的应用及检测CHL的方法 |
CN111234252B (zh) * | 2020-02-24 | 2021-08-27 | 重庆师范大学 | 一种镉-有机超分子荧光聚合物及其制法与应用 |
-
2018
- 2018-06-21 CN CN201810642154.9A patent/CN108426867B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN108426867A (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108426867B (zh) | 在水中检测Fe3+和抗生素头孢曲松钠的MOF-Cd探针及其制备方法和应用 | |
Chen et al. | A novel intelligently integrated MOF-based ratio fluorescence sensor for ultra-sensitive monitoring of TC in water and food samples | |
CN103289684B (zh) | 一种荧光银纳米团簇及其制备方法和应用 | |
CN109799217B (zh) | 一种基于碲化镉量子点与铕离子复合体系的高灵敏度比率荧光探针及其制备方法和应用 | |
CN107290316B (zh) | 一种基于锆基mof的四环素荧光检测新方法 | |
CN108659833B (zh) | 一种黄色荧光碳点及其制备方法和应用 | |
CN108559096B (zh) | 一种检测水中抗生素污染物的发光金属有机框架材料 | |
CN107556305B (zh) | 一种用于检测铝离子荧光探针、制备方法及应用 | |
CN112029496B (zh) | 一种用于区分检测金属离子的荧光阵列传感器及其制备方法 | |
CN107417671B (zh) | 一种含喹啉取代的香豆素衍生物及其制备方法和在比率型pH荧光探针上的应用 | |
Yan et al. | Lanthanide metal-organic framework as a paper strip sensor for visual detection of sulfonamide with smartphone-based point-of-care platform | |
CN113234233B (zh) | 一种具有抗生素荧光识别的铕基金属-有机框架材料及制备方法 | |
Xu et al. | Killing two birds with one stone: Construction of a rare earth hybrid dual-channel fluorescent biosensor with intelligent broadcasting function and visualized synchronous assessment of multi-objectives | |
CN111100304A (zh) | 一种人体中多巴胺含量检测材料的制备方法 | |
CN103820103A (zh) | 一种检测汞离子的反应型罗丹明荧光探针及其制备方法 | |
CN110283100A (zh) | 一种化合物、制备方法及作为肼荧光探针的应用 | |
Wang et al. | Decoding and quantitative detection of antibiotics by a luminescent mixed-lanthanide-organic framework | |
CN116082654B (zh) | 一种镉金属配位聚合物及其制备方法和检测甲硝唑的应用 | |
CN109884015B (zh) | MOF-Zn荧光传感器在检测氯霉素中的应用及检测CHL的方法 | |
CN106861643A (zh) | 用于检测和吸附铜离子的双功能材料及其合成方法和应用 | |
CN117165284A (zh) | 检测四环素的比率荧光探针、试纸条及其制备方法和应用 | |
CN111545077A (zh) | 一种含稀土配合物混合基质膜的制备方法及其应用 | |
CN107607508B (zh) | 一种水溶性荧光化合物检测三价金离子的方法 | |
CN113340862B (zh) | 荧光分子传感器及制法、水中痕量铀酰离子的检测方法 | |
CN113930237A (zh) | 一种改性g-C3N4@MOF荧光复合材料及其制法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200626 |
|
CF01 | Termination of patent right due to non-payment of annual fee |